ClinicalTrials.gg
TerminatedNCT03890120PRIMISUpdated Nov 29, 2023Results posted

Study of Cilofexor in Adults With Primary Sclerosing Cholangitis

A Phase 3 interventional study of Cilofexor and Placebo in Primary Sclerosing Cholangitis, sponsored by Gilead Sciences. Terminated at 201 sites in 16 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2023-11-29.

Sponsored by Gilead Sciences · Phase 3, Interventional, and Treatment

Why this study was terminated
Following recommendation of the external Data Monitoring Committee, after it reviewed the results of a planned interim futility analysis.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
419
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 75 studies in Cholangitis, Sclerosing with a site in United States — 19 open to participants now, 22 under way, 2 of them phase 3. Cholangitis, Sclerosing · United States.

Enrollment
Largest of 57
419 · median 27
Started
2019
with 4 others
Phase 3
4 of 75
1 open now
Registered
47th of 75
by date
Lead sponsor
7 of 75
Gilead Sciences

Among the 75 studies in Cholangitis, Sclerosing with a site in United States, this one has the largest enrollment of the 57 interventional ones that give a count, is one of 5 that started in 2019, is one of 4 in phase 3, and was the 47th registered.

Cholangitis, Sclerosing

150 studies on the registry are indexed under Cholangitis, Sclerosing; 40 are open to participants now.

Browse Cholangitis, Sclerosing studies →

Open to participants now

19 of the 75 studies in Cholangitis, Sclerosing with a site in United States are open now. Recruiting first, the newest first:

14 more — sign in →

All 19 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 30 Cholangitis, Sclerosing studies recruiting now, 12 (40%) set no upper age limit and 13 (43%) stop at 75 or younger; 9 take children under 18; 9 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 75 studies in Cholangitis, Sclerosing with a site in United States, or all of them as a file.
02

Study summary

The primary objective of this study is to evaluate whether cilofexor reduces the risk of fibrosis progression among non-cirrhotic adults with primary sclerosing cholangitis (PSC).

03

Conditions studied

  • Primary Sclerosing Cholangitis
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Diagnosis of large duct PSC
  • Liver at screening that is deemed acceptable for interpretation and demonstrates stage F0 - F3 fibrosis in the opinion of the central reader
  • Individual has the following laboratory parameters at the screening visit, as determined by the central laboratory:

    • count ≥ 150,000/mm\^3
    • Estimated (eGFR) ≥ 30 milliliter/minute (mL/min), as calculated by the equation
    • (ALT) ≤ 8 x (ULN)
    • Total \< 2 mg/dL, unless the individual is known to have Gilbert's syndrome or hemolytic anemia
    • (INR) ≤ 1.4, unless due to therapeutic anticoagulation
    • Negative anti-mitochondrial antibody

Key Exclusion Criteria:

  • Current or prior history of any of the following:

    • Cirrhosis
    • Liver transplantation
    • Cholangiocarcinoma or hepatocellular carcinoma (HCC)
    • Ascending cholangitis within 30 days of screening
  • Presence of a percutaneous drain or biliary stent
  • Other causes of liver disease
  • Current or prior history of unstable cardiovascular disease
  • Current moderate to severe inflammatory bowel disease (IBD) (including ulcerative colitis, Crohn's disease, and indeterminate colitis)

Note: Other protocol defined Inclusion/Exclusion criteria may apply

Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
419 participants (actual)

Study arms

  • Experimental
    Cilofexor 100 mg (Blinded Phase)

    Participants received cilofexor 100 mg tablet, orally, once daily for up to 100.3 weeks.

    Drug: Cilofexor

  • Placebo comparator
    Placebo (Blinded Phase)

    Participants received placebo to match cilofexor 100 mg tablet, orally, once daily for up to 98.1 weeks.

    Drug: Placebo

  • Experimental
    Cilofexor From Cilofexor 100 mg (OLE Phase)

    Participants who received cilofexor in blinded phase and had entered the open-label extension (OLE) phase received open-label cilofexor 100 mg tablet, orally, once daily for up to 44.7 weeks.

    Drug: Cilofexor

  • Experimental
    Cilofexor From Placebo (OLE Phase)

    Participants who received placebo in blinded phase and had entered the OLE phase received open-label cilofexor 100 mg tablet, orally, once daily for up to 45.0 weeks.

    Drug: Cilofexor

Interventions

  • 100 mg tablet administered orally once daily

    Also known as: GS-9674

  • DrugPlacebo

    Tablet administered orally once daily

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Progression of Liver Fibrosis at Blinded Phase Week 96

    Progression of liver fibrosis was defined as having a ≥ 1-stage increase from baseline in fibrosis according to the Ludwig classification at Blinded Phase Week 96. The stages of fibrosis was assessed according to Ludwig classification. Ludwig classification fibrosis stages range from 0 to 4, with higher scores indicating greater fibrosis (0=no fibrosis, 4=cirrhosis).

    Time frame: Blinded Phase Week 96

Secondary outcomes

  1. Percentage of Participants Who Experienced Treatment-emergent Adverse Events (TEAEs) in The Blinded Phase

    An AE was any untoward medical occurrence in a clinical study participant administered a study drug that does not necessarily have a causal relationship with the treatment. An AE can therefore be any unfavorable and/or unintended sign, symptom, or disease temporally associated with the use of a study drug, whether or not the AE is considered related to the study drug. For Blinded Study Phase and OLE Phase, TEAEs were defined as 1 or both of the following: Any AEs with an onset date on or after the study drug start date and no later than 30 days after permanent discontinuation of study drug and/or any AEs leading to premature discontinuation of study drug.

    Time frame: First dose date in the Blinded Phase up to 100.3 weeks plus 30 days

  2. Percentage of Participants Who Experienced TEAEs in The OLE Phase

    An AE was any untoward medical occurrence in a clinical study participant administered a study drug that does not necessarily have a causal relationship with the treatment. An AE can therefore be any unfavorable and/or unintended sign, symptom, or disease temporally associated with the use of a study drug, whether or not the AE is considered related to the study drug. For Blinded Study Phase and OLE Phase, TEAEs were defined as 1 or both of the following: Any AEs with an onset date on or after the study drug start date and no later than 30 days after permanent discontinuation of study drug and/or any AEs leading to premature discontinuation of study drug.

    Time frame: First dose date in the OLE Phase up to 45 weeks plus 30 days

  3. Percentage of Participants Who Experienced Treatment-emergent Serious Adverse Events (SAEs) in the Blinded Phase

    An SAE was defined as an event that, at any dose, results in the following: death, a life-threatening situation; in-patient hospitalization or prolongation of existing hospitalization, persistent or significant disability/incapacity, a congenital anomaly/birth defect or a medically important event or reaction.

    Time frame: First dose date in the Blinded Phase up to 100.3 weeks plus 30 days

  4. Percentage of Participants Who Experienced Treatment-emergent SAEs in the OLE Phase

    An SAE was defined as an event that, at any dose, results in the following: death, a life-threatening situation; in-patient hospitalization or prolongation of existing hospitalization, persistent or significant disability/incapacity, a congenital anomaly/birth defect or a medically important event or reaction.

    Time frame: First dose date in the OLE Phase up to 45 weeks plus 30 days

  5. Change From Baseline in Serum Concentrations of Alkaline Phosphatase (ALP) at Blinded Phase Week 96

    Time frame: Baseline, Blinded Phase Week 96

  6. Change From Baseline in Serum Concentrations of Alanine Aminotransferase (ALT) at Blinded Phase Week 96

    Time frame: Baseline, Blinded Phase Week 96

  7. Change From Baseline in Serum Concentrations of Fasting Total Bile Acids at Blinded Phase Week 96

    Time frame: Baseline, Blinded Phase Week 96

  8. Percentage of Participants With ≥ 25% Relative Reduction in Serum ALP Concentration From Baseline and No Worsening of Fibrosis According to the Ludwig Classification at Blinded Phase Week 96

    The stages of fibrosis was assessed according to Ludwig classification. Ludwig classification fibrosis stages range from 0 to 4, with higher scores indicating greater fibrosis (0=no fibrosis, 4=cirrhosis).The percentage of participants with ≥ 25% reduction in serum ALP Concentration from baseline and no increase in fibrosis according to the Ludwig Classification at Blinded Phase Week 96 was analyzed.

    Time frame: Baseline, Blinded Phase Week 96

  9. Percentage of Participants With Fibrosis Improvement According to the Ludwig Classification at Blinded Phase Week 96

    Fibrosis improvement was defined as having ≥ 1-stage decrease from baseline in fibrosis according to the Ludwig classification score at Blinded Study Phase Week 96. The stages of fibrosis was assessed according to Ludwig classification. Ludwig classification fibrosis stages range from 0 to 4, with higher scores indicating greater fibrosis (0=no fibrosis, 4=cirrhosis).

    Time frame: Blinded Phase Week 96

  10. Change From Baseline in Primary Sclerosing Cholangitis (PSC) Symptoms - Module 1 Based on Disease-specific Patient Reported Outcome (PSC-PRO) at Blinded Phase Week 96

    The PSC-PRO addressed the severity of common everyday symptoms of PSC (eg, pruritus, fatigue, and right upper quadrant abdominal discomfort); and their functional impact (eg, on physical function, activities of daily living, and work productivity, etc). PSC-PRO module 1 - PSC symptoms contains a total of 12 questions asking about the severity of specific PSC symptoms on a scale of 0 (no symptoms) to 10 (symptoms as bad as you could imagine) with a 24-hour recall period. The total score, which is computed as 12 times the average of nonmissing scores of the 12 questions, can potentially range between 0 and 120, with higher scores indicating more severe symptoms. A positive change from baseline indicates worsening of symptoms.

    Time frame: Baseline, Blinded Phase Week 96

  11. Change From Baseline in Enhanced Liver Fibrosis (ELF™ ) Test Score at Blinded Phase Week 96

    The Enhanced Liver Fibrosis (ELF™) test is a composite of three serum biomarkers of hepatobiliary fibrosis: hyaluronic acid, procollagen III amino-terminal peptide, and tissue inhibitor of metalloproteinase. A typical range for ELF™ test scores in PSC is between 6 and 14. Higher ELF™ test scores are associated with more severe liver disease. A positive change from baseline indicated worsening of fibrosis.

    Time frame: Baseline, Blinded Phase Week 96

  12. Change From Baseline in Liver Stiffness by FibroScan® at Blinded Phase Week 96

    Change in liver stiffness was measured by FibroScan® scores. FibroScan measures liver scarring by measuring the stiffness of the liver. It's normally between 2 and 6 kPa. Many people with liver disease(s) have a result that's higher than the normal range. Higher scores indicate increased scarring of the liver. A positive change from baseline indicates severe liver disease(s).

    Time frame: Baseline, Blinded Phase Week 96

07

Results

Posted Nov 29, 2023

Participant flow

Participants were enrolled at study sites in Europe, North America, Oceania, and Asia.

Blinded Treatment Phase (100.3 Weeks)
Participant flow — Blinded Treatment Phase (100.3 Weeks)
MilestoneCilofexor 100 mg (Blinded Phase)Placebo (Blinded Phase)Cilofexor From Cilofexor 100 mg (OLE Phase)Cilofexor From Placebo (OLE Phase)
Started27814100
Completed1236600
Not completed1557500
Withdrew: Study terminated by sponsor1195700
Withdrew: Adverse event17700
Withdrew: Withdrew consent12400
Withdrew: Lost to follow-up4100
Withdrew: Investigator's discretion1200
Withdrew: Randomized but never treated1200
Withdrew: Death1000
Withdrew: Non-compliance with study drug0100
Withdrew: Pregnancy0100
Open-Label Extension Phase (45 Weeks)
Participant flow — Open-Label Extension Phase (45 Weeks)
MilestoneCilofexor 100 mg (Blinded Phase)Placebo (Blinded Phase)Cilofexor From Cilofexor 100 mg (OLE Phase)Cilofexor From Placebo (OLE Phase)
Started008045
Completed0000
Not completed008045
Withdrew: Study terminated by sponsor007642
Withdrew: Adverse event0031
Withdrew: Lost to follow-up0002
Withdrew: Withdrew consent0010

Outcome measures

PrimaryPercentage of Participants With Progression of Liver Fibrosis at Blinded Phase Week 96

Progression of liver fibrosis was defined as having a ≥ 1-stage increase from baseline in fibrosis according to the Ludwig classification at Blinded Phase Week 96. The stages of fibrosis was assessed according to Ludwig classification. Ludwig classification fibrosis stages range from 0 to 4, with higher scores indicating greater fibrosis (0=no fibrosis, 4=cirrhosis).

Time frame:
Blinded Phase Week 96
Reported as:
Number · percentage of participants
Percentage of Participants With Progression of Liver Fibrosis at Blinded Phase Week 96
percentage of participantsCilofexor 100 mg (Blinded Phase)Placebo (Blinded Phase)
Percentage of Participants With Progression of Liver Fibrosis at Blinded Phase Week 9630.832.8
Statistical analysis
  • Cilofexor 100 mg (Blinded Phase) vs Placebo (Blinded Phase) · Mantel Haenszel · p = 0.4186 · Difference in percentages: -1.4 · 95% CI -15.2 to 12.3The difference of cilofexor and placebo,95% confidence interval(CI),and P value(1-sided)were obtained by the stratum-adjusted Mantel-Haenszel (MH) method,with baseline ursodeoxycholic acid(UDCA)use and Ludwig fibrosis stage as stratification factors.
SecondaryPercentage of Participants Who Experienced Treatment-emergent Adverse Events (TEAEs) in The Blinded Phase

An AE was any untoward medical occurrence in a clinical study participant administered a study drug that does not necessarily have a causal relationship with the treatment. An AE can therefore be any unfavorable and/or unintended sign, symptom, or disease temporally associated with the use of a study drug, whether or not the AE is considered related to the study drug. For Blinded Study Phase and OLE Phase, TEAEs were defined as 1 or both of the following: Any AEs with an onset date on or after the study drug start date and no later than 30 days after permanent discontinuation of study drug and/or any AEs leading to premature discontinuation of study drug.

Time frame:
First dose date in the Blinded Phase up to 100.3 weeks plus 30 days
Reported as:
Number · percentage of participants
Percentage of Participants Who Experienced Treatment-emergent Adverse Events (TEAEs) in The Blinded Phase
percentage of participantsCilofexor 100 mg (Blinded Phase)Placebo (Blinded Phase)
Percentage of Participants Who Experienced Treatment-emergent Adverse Events (TEAEs) in The Blinded Phase97.195.0
SecondaryPercentage of Participants Who Experienced TEAEs in The OLE Phase

An AE was any untoward medical occurrence in a clinical study participant administered a study drug that does not necessarily have a causal relationship with the treatment. An AE can therefore be any unfavorable and/or unintended sign, symptom, or disease temporally associated with the use of a study drug, whether or not the AE is considered related to the study drug. For Blinded Study Phase and OLE Phase, TEAEs were defined as 1 or both of the following: Any AEs with an onset date on or after the study drug start date and no later than 30 days after permanent discontinuation of study drug and/or any AEs leading to premature discontinuation of study drug.

Time frame:
First dose date in the OLE Phase up to 45 weeks plus 30 days
Reported as:
Number · percentage of participants
Percentage of Participants Who Experienced TEAEs in The OLE Phase
percentage of participantsCilofexor From Cilofexor 100 mg (OLE Phase)Cilofexor From Placebo (OLE Phase)
Percentage of Participants Who Experienced TEAEs in The OLE Phase66.373.3
SecondaryPercentage of Participants Who Experienced Treatment-emergent Serious Adverse Events (SAEs) in the Blinded Phase

An SAE was defined as an event that, at any dose, results in the following: death, a life-threatening situation; in-patient hospitalization or prolongation of existing hospitalization, persistent or significant disability/incapacity, a congenital anomaly/birth defect or a medically important event or reaction.

Time frame:
First dose date in the Blinded Phase up to 100.3 weeks plus 30 days
Reported as:
Number · percentage of participants
Percentage of Participants Who Experienced Treatment-emergent Serious Adverse Events (SAEs) in the Blinded Phase
percentage of participantsCilofexor 100 mg (Blinded Phase)Placebo (Blinded Phase)
Percentage of Participants Who Experienced Treatment-emergent Serious Adverse Events (SAEs) in the Blinded Phase19.118.7
SecondaryPercentage of Participants Who Experienced Treatment-emergent SAEs in the OLE Phase

An SAE was defined as an event that, at any dose, results in the following: death, a life-threatening situation; in-patient hospitalization or prolongation of existing hospitalization, persistent or significant disability/incapacity, a congenital anomaly/birth defect or a medically important event or reaction.

Time frame:
First dose date in the OLE Phase up to 45 weeks plus 30 days
Reported as:
Number · percentage of participants
Percentage of Participants Who Experienced Treatment-emergent SAEs in the OLE Phase
percentage of participantsCilofexor From Cilofexor 100 mg (OLE Phase)Cilofexor From Placebo (OLE Phase)
Percentage of Participants Who Experienced Treatment-emergent SAEs in the OLE Phase11.32.2
SecondaryChange From Baseline in Serum Concentrations of Alkaline Phosphatase (ALP) at Blinded Phase Week 96
Time frame:
Baseline, Blinded Phase Week 96
Reported as:
Least squares mean · units per liter (U/L)
Change From Baseline in Serum Concentrations of Alkaline Phosphatase (ALP) at Blinded Phase Week 96
units per liter (U/L)Cilofexor 100 mg (Blinded Phase)Placebo (Blinded Phase)
Change From Baseline in Serum Concentrations of Alkaline Phosphatase (ALP) at Blinded Phase Week 960 (-17 to 16)3 (-19 to 25)
Statistical analysis
  • Cilofexor 100 mg (Blinded Phase) vs Placebo (Blinded Phase) · ANCOVA · p = 0.3884 · Difference in least squares mean (lsm): -4 · 95% CI -28 to 21The LSM,95% CI and P-value(1-sided) were obtained by an analysis of covariance(ANCOVA)model with change at Week 96 as dependent variable,baseline value of outcome measure,baseline UDCA use, and baseline Ludwig fibrosis stage as independent variables.
SecondaryChange From Baseline in Serum Concentrations of Alanine Aminotransferase (ALT) at Blinded Phase Week 96
Time frame:
Baseline, Blinded Phase Week 96
Reported as:
Least squares mean · U/L
Change From Baseline in Serum Concentrations of Alanine Aminotransferase (ALT) at Blinded Phase Week 96
U/LCilofexor 100 mg (Blinded Phase)Placebo (Blinded Phase)
Change From Baseline in Serum Concentrations of Alanine Aminotransferase (ALT) at Blinded Phase Week 96-13 (-20 to -6)-3 (-12 to 6)
Statistical analysis
  • Cilofexor 100 mg (Blinded Phase) vs Placebo (Blinded Phase) · ANCOVA · p = 0.0390 · Difference in lsm: -9 · 95% CI -20 to 1The LSM, 95% CI and P-value (1-sided) were obtained by ANCOVA model to evaluate change at Week 96 as the dependent variable, baseline value of the outcome measure, baseline UDCA use, and baseline Ludwig fibrosis stage as independent variables.
SecondaryChange From Baseline in Serum Concentrations of Fasting Total Bile Acids at Blinded Phase Week 96
Time frame:
Baseline, Blinded Phase Week 96
Reported as:
Least squares mean · micromoles per liter (μmol/L)
Change From Baseline in Serum Concentrations of Fasting Total Bile Acids at Blinded Phase Week 96
micromoles per liter (μmol/L)Cilofexor 100 mg (Blinded Phase)Placebo (Blinded Phase)
Change From Baseline in Serum Concentrations of Fasting Total Bile Acids at Blinded Phase Week 967.2 (0.9 to 13.5)9.8 (1.8 to 17.9)
Statistical analysis
  • Cilofexor 100 mg (Blinded Phase) vs Placebo (Blinded Phase) · ANCOVA · p = 0.2845 · Difference in lsm: -2.6 · 95% CI -11.6 to 6.4The LSM, 95% CI and P-value (1-sided) were obtained by ANCOVA model to evaluate change at Week 96 as the dependent variable, baseline value of the outcome measure, baseline UDCA use, and baseline Ludwig fibrosis stage as independent variables.
SecondaryPercentage of Participants With ≥ 25% Relative Reduction in Serum ALP Concentration From Baseline and No Worsening of Fibrosis According to the Ludwig Classification at Blinded Phase Week 96

The stages of fibrosis was assessed according to Ludwig classification. Ludwig classification fibrosis stages range from 0 to 4, with higher scores indicating greater fibrosis (0=no fibrosis, 4=cirrhosis).The percentage of participants with ≥ 25% reduction in serum ALP Concentration from baseline and no increase in fibrosis according to the Ludwig Classification at Blinded Phase Week 96 was analyzed.

Time frame:
Baseline, Blinded Phase Week 96
Reported as:
Number · percentage of participants
Percentage of Participants With ≥ 25% Relative Reduction in Serum ALP Concentration From Baseline and No Worsening of Fibrosis According to the Ludwig Classification at Blinded Phase Week 96
percentage of participantsCilofexor 100 mg (Blinded Phase)Placebo (Blinded Phase)
Percentage of Participants With ≥ 25% Relative Reduction in Serum ALP Concentration From Baseline and No Worsening of Fibrosis According to the Ludwig Classification at Blinded Phase Week 969.86.6
Statistical analysis
  • Cilofexor 100 mg (Blinded Phase) vs Placebo (Blinded Phase) · Mantel Haenszel · p = 0.1978 · Difference in percentages: 4.1 · 95% CI -5.3 to 13.5The difference between cilofexor and Placebo, 95% CI, and the p-value (1-sided) were obtained by the stratum-adjusted MH method, with baseline UDCA use and Ludwig fibrosis stage as stratification factors.
SecondaryPercentage of Participants With Fibrosis Improvement According to the Ludwig Classification at Blinded Phase Week 96

Fibrosis improvement was defined as having ≥ 1-stage decrease from baseline in fibrosis according to the Ludwig classification score at Blinded Study Phase Week 96. The stages of fibrosis was assessed according to Ludwig classification. Ludwig classification fibrosis stages range from 0 to 4, with higher scores indicating greater fibrosis (0=no fibrosis, 4=cirrhosis).

Time frame:
Blinded Phase Week 96
Reported as:
Number · percentage of participants
Percentage of Participants With Fibrosis Improvement According to the Ludwig Classification at Blinded Phase Week 96
percentage of participantsCilofexor 100 mg (Blinded Phase)Placebo (Blinded Phase)
Percentage of Participants With Fibrosis Improvement According to the Ludwig Classification at Blinded Phase Week 9625.617.2
Statistical analysis
  • Cilofexor 100 mg (Blinded Phase) vs Placebo (Blinded Phase) · Mantel Haenszel · p = 0.0797 · Difference in percentages: 8.9 · 95% CI -3.5 to 21.2The difference between cilofexor and Placebo, 95% CI, and the p-value (1-sided) were obtained by the stratum-adjusted MH method, with baseline UDCA use and Ludwig fibrosis stage as stratification factors.
SecondaryChange From Baseline in Primary Sclerosing Cholangitis (PSC) Symptoms - Module 1 Based on Disease-specific Patient Reported Outcome (PSC-PRO) at Blinded Phase Week 96

The PSC-PRO addressed the severity of common everyday symptoms of PSC (eg, pruritus, fatigue, and right upper quadrant abdominal discomfort); and their functional impact (eg, on physical function, activities of daily living, and work productivity, etc). PSC-PRO module 1 - PSC symptoms contains a total of 12 questions asking about the severity of specific PSC symptoms on a scale of 0 (no symptoms) to 10 (symptoms as bad as you could imagine) with a 24-hour recall period. The total score, which is computed as 12 times the average of nonmissing scores of the 12 questions, can potentially range between 0 and 120, with higher scores indicating more severe symptoms. A positive change from baseline indicates worsening of symptoms.

Time frame:
Baseline, Blinded Phase Week 96
Reported as:
Mean · score on a scale
Change From Baseline in Primary Sclerosing Cholangitis (PSC) Symptoms - Module 1 Based on Disease-specific Patient Reported Outcome (PSC-PRO) at Blinded Phase Week 96
score on a scaleCilofexor 100 mg (Blinded Phase)Placebo (Blinded Phase)
Baseline11 ± 11.011 ± 11.8
Change at Blinded Phase Week 961 ± 9.00 ± 6.8
Statistical analysis
  • Cilofexor 100 mg (Blinded Phase) vs Placebo (Blinded Phase) · ANCOVA · p = 0.7275 · Difference in lsm: 1 · 95% CI -1 to 3The LSM, 95% CI and P-value (1-sided) were obtained by ANCOVA model to evaluate change at Week 96 as the dependent variable, baseline value of the outcome measure, baseline UDCA use, and baseline Ludwig fibrosis stage as independent variables.
SecondaryChange From Baseline in Enhanced Liver Fibrosis (ELF™ ) Test Score at Blinded Phase Week 96

The Enhanced Liver Fibrosis (ELF™) test is a composite of three serum biomarkers of hepatobiliary fibrosis: hyaluronic acid, procollagen III amino-terminal peptide, and tissue inhibitor of metalloproteinase. A typical range for ELF™ test scores in PSC is between 6 and 14. Higher ELF™ test scores are associated with more severe liver disease. A positive change from baseline indicated worsening of fibrosis.

Time frame:
Baseline, Blinded Phase Week 96
Reported as:
Least squares mean · score on a scale
Change From Baseline in Enhanced Liver Fibrosis (ELF™ ) Test Score at Blinded Phase Week 96
score on a scaleCilofexor 100 mg (Blinded Phase)Placebo (Blinded Phase)
Change From Baseline in Enhanced Liver Fibrosis (ELF™ ) Test Score at Blinded Phase Week 960.27 (0.16 to 0.38)0.30 (0.15 to 0.45)
Statistical analysis
  • Cilofexor 100 mg (Blinded Phase) vs Placebo (Blinded Phase) · ANCOVA · p = 0.3636 · Difference in lsm: -0.03 · 95% CI -0.20 to 0.14The LSM, 95% CI and P-value (1-sided) were obtained by ANCOVA model to evaluate change at Week 96 as the dependent variable, baseline value of the outcome measure, baseline UDCA use, and baseline Ludwig fibrosis stage as independent variables.
SecondaryChange From Baseline in Liver Stiffness by FibroScan® at Blinded Phase Week 96

Change in liver stiffness was measured by FibroScan® scores. FibroScan measures liver scarring by measuring the stiffness of the liver. It's normally between 2 and 6 kPa. Many people with liver disease(s) have a result that's higher than the normal range. Higher scores indicate increased scarring of the liver. A positive change from baseline indicates severe liver disease(s).

Time frame:
Baseline, Blinded Phase Week 96
Reported as:
Least squares mean · kilopascals (kPa)
Change From Baseline in Liver Stiffness by FibroScan® at Blinded Phase Week 96
kilopascals (kPa)Cilofexor 100 mg (Blinded Phase)Placebo (Blinded Phase)
Change From Baseline in Liver Stiffness by FibroScan® at Blinded Phase Week 962.4 (1.2 to 3.6)2.8 (1.1 to 4.4)
Statistical analysis
  • Cilofexor 100 mg (Blinded Phase) vs Placebo (Blinded Phase) · ANCOVA · p = 0.3595 · Difference in lsm: -0.3 · 95% CI -2.2 to 1.5The LSM, 95% CI and P-value (1-sided) were obtained by ANCOVA model to evaluate change at Week 96 as the dependent variable, baseline value of the outcome measure, baseline UDCA use, and baseline Ludwig fibrosis stage as independent variables.

Adverse events

Collected over All-cause mortality: Randomization up to 3.4 years; Adverse events: Blinded Phase: First dose date in the Blinded Phase up to 100.3 weeks plus 30 days; Open-Label Extension (OLE) Phase: First dose date in the OLE Phase up to 45 weeks plus 30 days. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Cilofexor 100 mg (Blinded Phase)2/278 (0.7%)53/277 (19.1%)232/277 (83.8%)
Placebo (Blinded Phase)0/141 (0%)26/139 (18.7%)109/139 (78.4%)
Cilofexor From Cilofexor 100 mg (OLE Phase)0/80 (0%)9/80 (11.3%)34/80 (42.5%)
Cilofexor From Placebo (OLE Phase)0/45 (0%)1/45 (2.2%)24/45 (53.3%)
Most frequent serious events
Showing 10 of 85
Most frequent serious events
EventCilofexor 100 mg (Blinded Phase)Placebo (Blinded Phase)Cilofexor From Cilofexor 100 mg (OLE Phase)Cilofexor From Placebo (OLE Phase)
CholangitisHepatobiliary disorders10/2777/1392/801/45
PyrexiaGeneral disorders4/2771/1390/800/45
Cholangitis acuteHepatobiliary disorders4/2770/1390/800/45
Cholecystitis acuteHepatobiliary disorders4/2770/1390/800/45
Bile duct stenosisHepatobiliary disorders1/2772/1390/800/45
CholangiocarcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/2772/1390/800/45
Abdominal painGastrointestinal disorders3/2770/1391/800/45
Abdominal pain upperGastrointestinal disorders2/2770/1391/800/45
Obstructive pancreatitisGastrointestinal disorders0/2770/1391/800/45
GastroenteritisInfections and infestations0/2770/1391/800/45
Most frequent other events
Showing 10 of 19
Most frequent other events
EventCilofexor 100 mg (Blinded Phase)Placebo (Blinded Phase)Cilofexor From Cilofexor 100 mg (OLE Phase)Cilofexor From Placebo (OLE Phase)
PruritusSkin and subcutaneous tissue disorders135/27750/13914/8011/45
Covid-19Infections and infestations65/27726/13911/8011/45
FatigueGeneral disorders34/27724/1393/800/45
Abdominal pain upperGastrointestinal disorders40/27720/1391/802/45
Abdominal painGastrointestinal disorders38/27717/1391/800/45
HeadacheNervous system disorders32/27718/1391/800/45
NauseaGastrointestinal disorders34/27716/1394/800/45
PyrexiaGeneral disorders33/2779/1393/802/45
ArthralgiaMusculoskeletal and connective tissue disorders15/27714/1392/800/45
NasopharyngitisInfections and infestations15/27712/1390/801/45

Baseline characteristics

Safety Analysis Set included all participants who took at least 1 dose of study drug.

Age, Categorical
Age, Categorical(Participants)Cilofexor 100 mg (Blinded Phase)Placebo (Blinded Phase)Total
<=18 years101
Between 18 and 65 years258133391
>=65 years18624
Age, Continuous
Age, Continuous(years)Cilofexor 100 mg (Blinded Phase)Placebo (Blinded Phase)Total
Mean43 ± 13.144 ± 12.844 ± 13.0
Sex: Female, Male
Sex: Female, Male(Participants)Cilofexor 100 mg (Blinded Phase)Placebo (Blinded Phase)Total
Female10752159
Male17087257
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Cilofexor 100 mg (Blinded Phase)Placebo (Blinded Phase)Total
Hispanic or Latino11314
Not Hispanic or Latino258130388
Unknown or Not Reported8614
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Cilofexor 100 mg (Blinded Phase)Placebo (Blinded Phase)Total
Race — White228117345
Race — Asian281038
Race — Black or African American10717
Race — Unknown or Not Reported6511
Race — Other or More Than One Race505
Region of Enrollment
Region of Enrollment(Participants)Cilofexor 100 mg (Blinded Phase)Placebo (Blinded Phase)Total
United States11457171
Japan19827
United Kingdom11819
Switzerland246
Spain13316
New Zealand426
Canada281038
Austria314
Belgium426
Finland11819
Denmark437
Italy17623
Israel8311
Australia181331
France8614
Germany13518
Alkaline Phosphatase (ALP)
Alkaline Phosphatase (ALP)(units per liter (U/L))Cilofexor 100 mg (Blinded Phase)Placebo (Blinded Phase)Total
Mean223 ± 177.7243 ± 189.5230 ± 181.7
Aspartate Aminotransferase (AST)
Aspartate Aminotransferase (AST)(U/L)Cilofexor 100 mg (Blinded Phase)Placebo (Blinded Phase)Total
Mean49 ± 34.151 ± 34.650 ± 34.2

3 further baseline measures are reported on the registry.

08

Study locations

201 sites
  • Institute For Liver Health
    Glendale, Arizona 85306, United States
  • The Institute for Liver Heath
    Phoenix, Arizona 85013, United States
  • Southern California Research Center
    Coronado, California 92118, United States
  • Altman Clinical and Translational Research Institute (Clinic)
    La Jolla, California 92037, United States
  • Scripps Clinic/Green Hospital
    La Jolla, California 92037, United States
  • Ruane Clinical Research Group Inc.
    Los Angeles, California 90036, United States
  • Stanford Hospital
    Palo Alto, California 94025, United States
  • California Liver Research Institute
    Pasadena, California 91105, United States
  • University of California, Davis Medical Center (study visits)
    Sacramento, California 95817, United States
  • Sutter Pacific Medical Foundation - California Pacific Medical Center
    San Francisco, California 94107, United States
  • University of California, San Francisco Liver Clinic
    San Francisco, California 94143, United States
  • Cedars Sinai Medical Center
    West Hollywood, California 90048, United States
  • University of Colorado Denver and Hospital
    Aurora, Colorado 80045, United States
  • Peak Gastroenterology Associates
    Colorado Springs, Colorado 80907, United States
  • South Denver Gastroenterology, PC
    Englewood, Colorado 80113, United States
  • Yale School of Medicine
    New Haven, Connecticut 48109, United States
  • MedStar Georgetown University Hospital
    Washington, District of Columbia 20007, United States
  • Schiff Center for Liver Diseases/University of Miami
    Miami, Florida 33136, United States
  • Advanced Research Institute, Inc
    New Port Richey, Florida 34653, United States
  • Advanced Medical Research Center
    Port Orange, Florida 32127, United States
  • Cleveland Clinic Florida
    Weston, Florida 33331, United States
  • Piedmont Atlanta Hospital
    Atlanta, Georgia 30309, United States
  • Northwestern Memorial Hospital; Clinical Research Unit
    Chicago, Illinois 60611, United States
  • Rush University Medical Center
    Chicago, Illinois 60612, United States
  • University of Chicago Medical Center (outpatient clinic)
    Chicago, Illinois 60637, United States
  • NorthShore University Healthsystem
    Evanston, Illinois 60201, United States
  • IU Health University Hospital
    Indianapolis, Indiana 46202, United States
  • University of Kansas Hospital
    Kansas City, Kansas 66160, United States
  • Ochsner Clinic Foundation
    New Orleans, Louisiana 70121, United States
  • Louisiana Research Center, LLC
    Shreveport, Louisiana 71105, United States
  • Mercy Medical Center
    Baltimore, Maryland 21202, United States
  • Walter Reed National Military Medical Center
    Bethesda, Maryland 20889, United States
  • Massachusetts General Hospital
    Boston, Massachusetts 02114, United States
  • Beth Israel Deaconess Medical Center
    Boston, Massachusetts 02215, United States
  • NECCR PrimaCare Research, LLC
    Fall River, Massachusetts 02721, United States
  • Michigan Medicine - University of Michigan
    Ann Arbor, Michigan 48109, United States
  • Henry Ford Hospital
    Detroit, Michigan 48202, United States
  • Minnesota Gastroenterology, PA
    Maplewood, Minnesota 55117, United States
  • Mayo Clinic
    Rochester, Minnesota 55905, United States
  • Southern Therapy and Advanced Research LLC
    Jackson, Mississippi 39157, United States
  • Saint Louis University, Gastroenterology & Hepatology
    Saint Louis, Missouri 63104, United States
  • University of Nebraska Medical Center
    Omaha, Nebraska 68105, United States
  • Rutgers New Jersey Medical School - Doctors Office Center
    Newark, New Jersey 07103, United States
  • Montefiore Medical Center
    Bronx, New York 10467, United States
  • Northwell Health Center for Liver Diseases and Transplantation
    Manhasset, New York 11030, United States
  • NYU Langone Health
    New York, New York 10016, United States
  • Weill Cornell Medical College
    New York, New York 10021, United States
  • Icahn School of Medicine at Mount Sinai Beth Israel
    New York, New York 10029, United States
  • Mount Sinai Medical Center
    New York, New York 10029, United States
  • Center for Liver Disease and Transplantation, Columbia University Medical Center
    New York, New York 10032, United States
  • University of Rochester Medical Center
    Rochester, New York 14642, United States
  • The University of NC at Chapel Hill, Clinical and Translational Research Center (CTRC)
    Chapel Hill, North Carolina 27599, United States
  • Carolinas Medical Center - Center for Liver Disease
    Charlotte, North Carolina 28204, United States
  • Duke University Medical Center
    Durham, North Carolina 27710, United States
  • Wake Forest Baptist Health
    Winston-Salem, North Carolina 27157, United States
  • Holmes Hospital
    Cincinnati, Ohio 45267, United States
  • Penn State Health Milton S. Hershey Medical Center
    Hershey, Pennsylvania 17033, United States
  • Thomas Jefferson University
    Philadelphia, Pennsylvania 19107, United States
  • Einstein Medical Center
    Philadelphia, Pennsylvania 19141, United States
  • Reading Hospital
    West Reading, Pennsylvania 19611, United States
  • University Gastroenterology
    Providence, Rhode Island 02905, United States
  • Medical University of South Carolina
    Charleston, South Carolina 28204, United States
  • Rapid City Medical Center, LLP
    Rapid City, South Dakota 57701, United States
  • Methodist University Hospital
    Memphis, Tennessee 38104, United States
  • Vanderbilt University Medical Center - Digestive Disease Center
    Nashville, Tennessee 37232, United States
  • Texas Clinical Research Institute
    Arlington, Texas 76012, United States
  • The Liver Institute at Methodist Dallas Medical Center
    Dallas, Texas 75203, United States
  • Annette & Harold C. Simmons Transplant Institute @ Baylor University Medical Center at Dallas
    Dallas, Texas 75246, United States
  • Baylor Scott & White Medical Center at Fort Worth
    Fort Worth, Texas 76104, United States
  • Baylor College of Medicine - Advanced Liver Therapies
    Houston, Texas 77030, United States
  • Spring Gastroenterology Associates
    Humble, Texas 77338, United States
  • San Antonio Military Medical Center, Gastro/Hepatology
    San Antonio, Texas 78234, United States
  • Intermountain Medical Center - Transplant Services
    Murray, Utah 84107, United States
  • University of Utah Hospital
    Salt Lake City, Utah 84132, United States
  • The University of Vermont Medical Center
    Burlington, Vermont 05401, United States
  • University of Virginia Medical Center
    Charlottesville, Virginia 22908, United States
  • Verity Research Inc.
    Fairfax, Virginia 22031, United States
  • Bon Secours Richmond Community Hospital
    Richmond, Virginia 23226, United States
  • Virginia Commonwealth University Clinical Research Services Unit
    Richmond, Virginia 23298, United States
  • Virginia Mason Medical Center
    Seattle, Washington 98101, United States
  • Harborview Medical Center
    Seattle, Washington 98104, United States
  • Liver Institute Northwest
    Seattle, Washington 98105, United States
  • Royal Prince Alfred Hospital
    Camperdown, New South Wales 2050, Australia
  • St. Vincent's Hospital Sydney
    Darlinghurst, New South Wales 2010, Australia
  • Nepean Hospital
    Penrith, New South Wales 2751, Australia
  • Westmead Hospital
    Westmead, New South Wales 2145, Australia
  • Coral Sea Clinical Research Institute - Mackay
    Auchenflower, Queensland 4066, Australia
  • Royal Brisbane and Women's Hospital
    Herston, Queensland 4029, Australia
  • Mater Misericordiae Ltd
    South Brisbane, Queensland 4101, Australia
  • Monash Health
    Clayton, Victoria 3168, Australia
  • Austin Health
    Heidelberg, Victoria 3084, Australia
  • The Alfred Hospital
    Melbourne, Victoria 3004, Australia
  • The Royal Melbourne Hospital
    Parkville, Victoria 3050, Australia
  • Sir Charles Gairdner Hospital
    Nedlands, Western Australia 6009, Australia
  • Royal Perth Hospital
    Perth, Western Australia 6000, Australia
  • Landeskrankenanstalten-Betriebsgesellscaft - KABEG, Klinikum Klagenfurt am Wörthersee
    Klagenfurt am Wörthersee, 9020, Austria
  • Allgemeines Krankenhaus Wien
    Vienna, 1090, Austria
  • Hôpital Erasme - ULB
    Bruxelles, 10070, Belgium
  • Universitair Ziekenhuis Antwerpen
    Edegem, 2650, Belgium
  • Universitair Ziekenhuis Gent
    Gent, 9000, Belgium

Showing the first 100 of 201 sites across 16 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Trauner M, Chung C, Sterling K, Liu X, Lu X, Xu J, Tempany-Afdhal C, Goodman ZD, Farkkila M, Tanaka A, Trivedi P, Kowdley KV, Bowlus CL, Levy C, Myers RP. PRIMIS: design of a pivotal, randomized, phase 3 study evaluating the safety and efficacy of the nonsteroidal farnesoid X receptor agonist cilofexor in noncirrhotic patients with primary sclerosing cholangitis. BMC Gastroenterol. 2023 Mar 15;23(1):75. doi: 10.1186/s12876-023-02653-2. PubMed 36922785 ↗
  • Trauner M, Levy C, Tanaka A, Goodman Z, Thorburn D, et al. A Phase 3 Randomized, Double-blind, Placebo-controlled Study Evaluation the Efficacy and Safety of Cilofexor in Patients With Non-cirrhotic Patients With Primary Sclerosing Cholangitis. J Hepatol. 2023 June;78(S1):S12-S13.

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2019 to primary completion in Nov 2022, 43 months.

Results were first posted in Nov 2023, 1 year after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 25, 2019
First posted
Mar 26, 2019
StartActual
Mar 27, 2019
Primary completionActual
Nov 10, 2022
CompletionActual
Dec 23, 2022
Results first posted
Nov 29, 2023
Last update
Nov 29, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 29, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03890120
Lead sponsor
Gilead Sciences
Responsible party
Sponsor
First posted
Mar 26, 2019
Start date
Mar 27, 2019
Primary completion
Nov 10, 2022
Completion
Dec 23, 2022
Results posted
Nov 29, 2023
Last update
Nov 29, 2023

Study contacts

Gilead Study Director
study director · Gilead Sciences

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Nov 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cilofexor

Start the discussion